No Result
View All Result
  • Login
Saturday, September 5, 2026
FeeOnlyNews.com
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading
No Result
View All Result
FeeOnlyNews.com
No Result
View All Result
Home Markets

6 GLP-1 Risks That Hit Harder After 65 — Just As Medicare Starts Paying

by FeeOnlyNews.com
2 months ago
in Markets
Reading Time: 4 mins read
A A
0
6 GLP-1 Risks That Hit Harder After 65 — Just As Medicare Starts Paying
Share on FacebookShare on TwitterShare on LInkedIn


Starting July 1, Medicare began covering weight-loss drugs like Wegovy and Zepbound for a $50 monthly copay. For seniors who’d been staring down price tags north of $1,000, that’s a real breakthrough.

But here’s what most of the headlines skipped.

These drugs don’t behave the same way in a 70-year-old body as they do in a 40-year-old one. The upside is real. So is the downside — and after 65, that downside gets heavier.

As Dr. Rozalina McCoy, an endocrinologist at the University of Maryland School of Medicine, told The New York Times, the risk-benefit calculus for these drugs “is very different for older adults than for younger people” — because the potential for harm is greater.

I’m not here to talk you out of anything. These medications are remarkable for the right person. I’m here to make sure you walk into your doctor’s office knowing exactly what to ask.

Here are six things worth weighing before you fill that prescription.

1. You could lose muscle right when you can least afford to

Your body starts shedding muscle in your 30s, and the losses speed up after 60. That’s just aging.

Now add a GLP-1. The weight you lose on these drugs isn’t all fat. According to the American Diabetes Association, lean body mass can account for 15% to 40% of the total weight lost.

For a 40-year-old, that’s a nuisance. For a 75-year-old, muscle is what gets you out of a chair and up the stairs — and keeps you out of a nursing home.

The fix isn’t to skip the drug. It’s to protect your muscles while you’re on it — resistance training and enough protein, worked out with your doctor.

2. The side effects can leave you dangerously dehydrated

Nausea, vomiting, diarrhea. They’re common with GLP-1s, and a Yale School of Medicine review found older adults tend to get hit with these gut side effects more often than younger patients.

Here’s the part that matters. Those symptoms drain fluids fast, and dehydration in an older body brings dizziness, weakness, and falls.

Yale’s Dr. Alissa Chen flags exactly this: a higher fall risk in seniors on these drugs, driven by dehydration.

A fall at 40 is a bruise. A fall at 78 can be a broken hip and everything that follows.

3. Fast weight loss isn’t always the win it sounds like

We’ve been trained to cheer any drop on the scale. In older adults, it’s more complicated.

Rapid, significant weight loss later in life is linked to worse health outcomes, not better ones. Geriatricians interviewed by the AAMC noted an association between losing more than 10% of body weight and higher all-cause mortality, especially in older men.

That’s why good doctors treating seniors chase function, not a number. Can you carry the groceries? Play with the grandkids? That’s the real scoreboard.

One thing before we keep going — the financial world is louder and dumber than ever. Hot takes everywhere. Almost none of it is worth your time. I’ve spent 35+ years cutting through the noise so you don’t have to. Sign up for the free Money Talks Newsletter — 10 seconds, no spam, just the stuff that matters.

4. Your bones may be more fragile than the drug ads suggest

This one’s still being sorted out, so I’ll give it to you straight: The evidence is mixed.

But one 2026 study in the Journal of Clinical Endocrinology & Metabolism is worth knowing about. It followed more than 46,000 adults 65 and older with Type 2 diabetes. GLP-1 users had roughly an 11% higher risk of fragility fractures than those on other diabetes drugs.

Other research has found neutral or even protective effects on bone. So this isn’t settled science. It’s a question to raise with your doctor, especially if osteoporosis already runs in your health history.

5. They can scramble how your other medications work

GLP-1s work partly by slowing down your digestion. Food — and drugs — move through you more slowly.

Now picture the average 70-year-old’s medicine cabinet. Blood pressure pills, a statin, maybe a blood thinner, a thyroid tablet. Slower stomach emptying can change how those get absorbed.

Yale’s researchers warn that in older adults, these interactions can snowball into serious downstream effects. Bring your complete medication list to that first appointment. Every pill, every supplement.

6. The weight comes back when you stop — and this deal is temporary

Read the fine print on Medicare’s program: It’s a time-limited demonstration, currently set to run through the end of 2027. It’s a bridge, not a permanent benefit.

That matters, because when people stop taking GLP-1s, the weight tends to return. One analysis of eight trials found participants regained about 21 pounds within a year of stopping.

Here’s the cruel twist. You often lose fat and muscle on the way down, then regain mostly fat on the way back up. That leaves older bodies weaker than when they started. Don’t begin without an exit plan.

The bottom line

None of this means these drugs are bad. For the right older adult, under the right supervision, they can be life-changing.

But “over 65” isn’t a footnote on the label. It changes the whole equation.

Yale endocrinologist Dr. Kasia Lipska said it plainly: “We still don’t have clear evidence on how they perform in people over 65.”

So don’t let a $50 copay rush the decision. Bring the questions in this article to a doctor who knows your history — and make the call together.



Source link

Tags: GLP1harderhitMedicarePayingRisksstarts
ShareTweetShare
Previous Post

eVTOL Aircraft Market: Trends, Growth Drivers, & Future Outlook

Next Post

Dwayne Betts on the Iliad

Related Posts

All signs are pointing to the total and imminent collapse of the United States housing market.

All signs are pointing to the total and imminent collapse of the United States housing market.

by FeeOnlyNews.com
August 7, 2026
0

All signs are pointing to the total and imminent collapse of the United States housing market.What is about to happen...

Cities holding up to 3 million people found under Amazon rain forest

Cities holding up to 3 million people found under Amazon rain forest

by FeeOnlyNews.com
August 7, 2026
0

Archaeologists have officially discovered a massive, completely lost ancient civilization hidden deep beneath the Amazon rainforest using advanced LiDAR laser...

nLIGHT Releases Q2 2026 Financial Results

nLIGHT Releases Q2 2026 Financial Results

by FeeOnlyNews.com
August 7, 2026
0

AlphaStreet Newsdesk powered by AlphaStreet Intelligence LASR|EPS $0.15 vs $0.14 est (+7.1%)|Rev $82.6M|Net Loss $1.3M Q2 2026 non-GAAP earnings at...

The  Burrito Debate Reveals GOP’s Affordability Rift

The $20 Burrito Debate Reveals GOP’s Affordability Rift

by FeeOnlyNews.com
August 7, 2026
0

Sometimes a burrito isn’t just a burrito. What started as a complaint about a $20 burrito has turned into one...

Doximity shares double. Here’s what’s driving it 

Doximity shares double. Here’s what’s driving it 

by FeeOnlyNews.com
August 7, 2026
0

Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021.Source: NYSEShares of medical platform...

E.W. Scripps Q2 2026 Loss Widens to -.68/Share, Revenue Down 9%

E.W. Scripps Q2 2026 Loss Widens to -$12.68/Share, Revenue Down 9%

by FeeOnlyNews.com
August 7, 2026
0

AlphaStreet Newsdesk powered by AlphaStreet Intelligence SSP|Loss Per Share $12.68 vs -$0.40 est (-3070.0%)|Rev $490.4M|Net Loss $1.15B Stock $2.95 (+2.8%)...

Next Post
He Started with ,000. Now He Owns 14 Rental Properties (And Quit His Job!)

He Started with $5,000. Now He Owns 14 Rental Properties (And Quit His Job!)

She Bought the Property No One Wanted. It Had a Hidden Income Stream (K+/Month).

She Bought the Property No One Wanted. It Had a Hidden Income Stream ($3K+/Month).

  • Trending
  • Comments
  • Latest
Bitcoin and ethereum prices today, Friday, August 7, 2026: Crypto prices moving higher following July jobs report

Bitcoin and ethereum prices today, Friday, August 7, 2026: Crypto prices moving higher following July jobs report

August 7, 2026
MEXC Lists Ondo Yield Asset As Tokenized Treasury Demand Grows

MEXC Lists Ondo Yield Asset As Tokenized Treasury Demand Grows

July 3, 2026
Delek Logistics Partners Reports alt=

Delek Logistics Partners Reports $0.54 EPS for Q2 FY26

August 5, 2026
Onkure Therapeutics Releases Q2 2026 Financial Results

Onkure Therapeutics Releases Q2 2026 Financial Results

August 4, 2026
Thryv outlines M run-rate savings while revising 2026 SaaS adjusted EBITDA to M-M (NASDAQ:THRY)

Thryv outlines $60M run-rate savings while revising 2026 SaaS adjusted EBITDA to $42M-$44M (NASDAQ:THRY)

August 4, 2026
My Thoughts on Going All In

My Thoughts on Going All In

August 4, 2026
Advanced Micro Devices (AMD) Price Prediction: How Much a ,000 Investment Could Be Worth by 2031

Advanced Micro Devices (AMD) Price Prediction: How Much a $5,000 Investment Could Be Worth by 2031

0
Cities holding up to 3 million people found under Amazon rain forest

Cities holding up to 3 million people found under Amazon rain forest

0
Republican Party Displacement | Mises Institute

Republican Party Displacement | Mises Institute

0
Bybit Uses Tokenised Equities as Underlyings for Structured Yield

Bybit Uses Tokenised Equities as Underlyings for Structured Yield

0
Explained: How BSE traded fewer contracts after CAS but premiums rose 75% in first week

Explained: How BSE traded fewer contracts after CAS but premiums rose 75% in first week

0
Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT)

Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT)

0
Advanced Micro Devices (AMD) Price Prediction: How Much a ,000 Investment Could Be Worth by 2031

Advanced Micro Devices (AMD) Price Prediction: How Much a $5,000 Investment Could Be Worth by 2031

August 8, 2026
Republican Party Displacement | Mises Institute

Republican Party Displacement | Mises Institute

August 8, 2026
Vanguard Chief Economist: AI and jobs, still in an ATM phase

Vanguard Chief Economist: AI and jobs, still in an ATM phase

August 8, 2026
Explained: How BSE traded fewer contracts after CAS but premiums rose 75% in first week

Explained: How BSE traded fewer contracts after CAS but premiums rose 75% in first week

August 8, 2026
Democrats’ Affordability Message Misses a Key Expense—Student Debt

Democrats’ Affordability Message Misses a Key Expense—Student Debt

August 8, 2026
Banks or NBFCs? DSP’s Preethi R S explains where she sees the best opportunities

Banks or NBFCs? DSP’s Preethi R S explains where she sees the best opportunities

August 8, 2026
FeeOnlyNews.com

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Economy
  • Financial Planning
  • Investing
  • Market Analysis
  • Markets
  • Money
  • Personal Finance
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Advanced Micro Devices (AMD) Price Prediction: How Much a $5,000 Investment Could Be Worth by 2031
  • Republican Party Displacement | Mises Institute
  • Vanguard Chief Economist: AI and jobs, still in an ATM phase
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclaimers
  • About Us
  • Contact Us

Copyright © 2022-2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Sign In with Facebook
Sign In with Google
Sign In with Linked In
OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Business
  • Financial Planning
  • Personal Finance
  • Investing
  • Money
  • Economy
  • Markets
  • Stocks
  • Trading

Copyright © 2022-2024 All Rights Reserved
See articles for original source and related links to external sites.